サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1643915

インターロイキン阻害剤の世界市場（2025年～2032年）

Global Interleukin Inhibitors Market - 2025-2032

出版日
ページ情報
英文 265 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.35円
インターロイキン阻害剤の世界市場（2025年～2032年）
出版日: 2025年01月27日
発行: DataM Intelligence
ページ情報: 英文 265 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のインターロイキン阻害剤の市場規模は、2024年に495億6,000万米ドルに達し、2032年には1,164億2,000万米ドルに達すると予測され、予測期間2025年～2032年のCAGRは8.5%で成長する見通しです。

パイプライン医薬品

インターロイキン阻害剤は、炎症経路の主要な媒介因子であり、身体の免疫系の調節因子であるインターロイキンの働きを抑制する薬剤です。インターロイキンは、乾癬、湿疹、炎症性腸疾患、関節リウマチ、喘息、心血管疾患、感染症など様々な慢性疾患の病態生理において重要な役割を果たしていることが判明しています。炎症性腸疾患の治療には、炎症性腸疾患の活性を抑制または変化させることが不可欠です。インターロイキン阻害剤は、インターロイキンに特異的なタンパク質であるレセプターを標的として選択的に作用します。この選択的阻害は、特定の疾患病態に関与する特定のインターロイキンをブロックするために不可欠です。現在、IL-1、IL-2、IL-6、IL-12、IL-17、IL23、IL-36などのような様々なインターロイキンを標的とするいくつかのインターロイキン阻害剤があります。

これらの阻害剤の市場は、慢性炎症性疾患の有病率の上昇、疾患病態生理学の理解の進歩、疑われるインターロイキンを標的とする特異的なインターロイキン阻害剤を開発するための研究開発活動への注力の高まりによって牽引されると予想されます。

市場力学：

促進要因と抑制要因

慢性炎症性疾患の有病率の上昇

慢性炎症性疾患の有病率と発症率の上昇は、インターロイキン阻害剤市場成長の重要な促進要因です。これらの薬剤は、慢性炎症性疾患の病態生理学において重要な役割を果たすインターロイキンを阻害することを目的としています。インターロイキン阻害剤を使用する主な症状は、乾癬、関節リウマチ、喘息、炎症性腸疾患、湿疹などです。これらの疾患の有病率が上昇するにつれて、インターロイキン阻害剤のような先進的な治療薬に対する需要も増加し、予測期間中の市場成長をプラスに推進すると予想されます。

例えば、DataM intelligenceの有病率予測によると、IBDの世界人口は2024年の493万人から2030年には543万人に達すると予想されています。罹患率も2024年の36万3,000件から2030年には38万6,000件に増加すると予測されています。

インターロイキン阻害剤の高コストが市場成長を抑制する可能性

インターロイキン阻害剤はいくつかの慢性炎症性疾患の治療に革命をもたらしていますが、コストが高いため採用率が低下する可能性があります。これは特に低・中所得国や保険償還のない患者に見られます。例えば、デュピクセント（デュピルマブ）は高価格のため、インターロイキン阻害剤の中で最も売れていますが、保険が適用されない患者には手が届かない可能性があります。保険が適用されない患者は、2回の注射につき定価の3,803.20米ドルよりも高い金額を支払わなければなりません。

セグメント分析

世界の市場セグメンテーション市場は、ターゲット、症状、流通チャネル、地域によって区分されます。

症状別では乾癬が市場を独占すると予想されます。

乾癬は、患者の皮膚に影響を及ぼす慢性の自己免疫疾患です。この疾患は、免疫細胞、特にインターロイキンの亢進に起因し、表皮の過形成と皮膚層への免疫細胞の浸潤を特徴とします。IL-23/IL-17軸はこの疾患の主要な促進因子であり、その活性化はサイトカイン、炎症性メディエーターの放出、そしてケラチノサイトの活性化といった事象の連続発生をもたらします。この活性化が過剰な炎症を引き起こし、最終的に乾癬と呼ばれる状態になります。乾癬には様々なタイプがありますが、その中でも斑状乾癬は、赤い斑状の皮膚と白い鱗屑を特徴とする最も一般的な乾癬です。さらに、乾癬患者は、乾癬性関節炎、重篤な心血管イベントなどの他の炎症性疾患を発症するリスクが高いです。

現在承認されているインターロイキン阻害剤は様々な慢性炎症性疾患に適応がありますが、そのほとんどは乾癬とその関連合併症の治療薬として最初に承認されたものです。しかし、乾癬の有病率も高く、全米乾癬財団によれば、乾癬に罹患している患者は全世界で1億2,500万人近くにのぼるとのことです。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 慢性炎症性疾患の発症率の上昇
      • 製品承認と市場アクセスの増加
    • 抑制要因
      • インターロイキン阻害剤の高コスト
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • 疫学
  • 価格分析
  • パイプライン分析
  • 特許分析
  • 規制分析

第6章 ターゲット別

  • インターロイキン-1
  • インターロイキン-2
  • インターロイキン-6
  • インターロイキン-12
  • インターロイキン-17
  • インターロイキン-23
  • その他

第7章 症状別

  • 乾癬
    • アトピー性皮膚炎
    • 関節炎
    • 喘息
    • 炎症性腸疾患（IBD）
    • その他

第8章 流通チャネル別

  • 院内薬局
  • 小売薬局
  • オンライン薬局

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ

第10章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第11章 企業プロファイル

  • Sanofi
    • 会社概要
    • 製品ポートフォリオ
      • 製品説明
      • 製品の主要業績評価指標（KPI）
      • 実績および予測の製品販売
      • 製品販売量
    • 財務概要
      • 企業収益
      • 地域別収益分配
      • 収益予測
    • 主な発展
      • 合併と買収
      • 主な製品開発活動
      • 規制当局の承認等
    • SWOT分析
  • Regeneron Pharmaceuticals, Inc.
  • Novartis AG
  • Eli Lilly and Company
  • GSK plc.
  • Johnson & Johnson Services, Inc.
  • AstraZeneca.
  • AbbVie.
  • F. Hoffmann-La Roche Ltd
  • Sun Pharmaceutical Industries, Inc.
  • Ortho Dermatologics'affiliated entities.
  • Sobi, Inc.
  • UCB, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • LEO Pharma Inc.
  • Kiniksa Pharmaceuticals.
  • Boehringer Ingelheim International GmbH.
  • Galderma Laboratories, L.P.
  • AnaptysBio, Inc.
    • パイプライン製品の説明
    • 製品の主要業績評価指標（KPI）
    • 主な活動
    • 市場参入のタイムライン
    • 製品普及率
    • 売上推定と予測
  • Huabo Biopharm (Shanghai) Co., Ltd.
  • CSL
  • DICE Therapeutics

第12章 付録

目次
Product Code: PH3503

The global interleukin inhibitors market reached US$ 49.56 billion in 2024 and is expected to reach US$ 116.42 billion by 2032, growing at a CAGR of 8.5% during the forecast period 2025-2032.

Pipeline Drugs

Interleukin inhibitors are the drugs that suppress the activity of interleukins, which are the major mediators in the inflammatory pathway and regulators of the body's immune system. Interleukins were found to play a crucial role in the pathophysiology of various chronic diseases such as psoriasis, eczema, inflammatory bowel disease, rheumatoid arthritis, asthma, cardiovascular conditions, infectious diseases, etc. Suppressing or modifying their activity is an essential mechanism in the treatment of aforementioned chronic diseases. Interleukin inhibitors act selectively by targeting receptors, proteins specific to the interleukin. This selective inhibition is essential to block a specific interleukin that is designated to play a role in particular disease pathology. Currently, there are several interleukin inhibitors targeting various interleukins such as IL-1, IL-2, IL-6, IL-12, IL-17, IL23, IL-36, etc.

The market for these inhibitors is expected to be driven by the rising prevalence of chronic inflammatory diseases, advancements in understanding disease pathophysiology, and increased focus on research and development activities to develop specific interleukin inhibitors that target the suspected interleukin.

Market Dynamics: Drivers & Restraints

The Rising Prevalence of Chronic Inflammatory Conditions

The rising prevalence and incidence of chronic inflammatory conditions is a significant driver for the interleukin inhibitors market growth. These drugs are aimed at inhibiting the interleukins that play a crucial role in chronic inflammatory disease pathophysiology. The major indications for interleukin inhibitors are psoriasis, rheumatoid arthritis, asthma, inflammatory bowel disease, eczema, etc. As the prevalence of these conditions rises, the demand for advanced therapies such as interleukin inhibitors is also expected to rise, propelling the market growth positively in the forecasted period.

For instance, as per DataM intelligence prevalence forecasts, the global population with IBD is expected to reach 5.43 million in 2030 from 4.93 million in 2024. The incidence rate is also expected to rise from 363k cases in 2024 to 386k cases in 2030.

High Cost of Interleukin Inhibitors may restrain the market growth.

Interleukin inhibitors are revolutionizing the treatment of several chronic inflammatory conditions, however, their higher cost may reduce their adoption rate. This is especially seen in low and middle-income countries, and patients who lack reimbursement. For instance, Dupixent (dupilumab) which is the top-selling interleukin inhibitor due to its high prices, may not be affordable for patients who lack insurance coverage. Patients who don't have insurance coverage have to pay more than the list price which is US$3,803.20 per 2 injections.

Segment Analysis

The global interleukin inhibitors market is segmented based on target, indication, distribution channel, and region.

Psoriasis in the indication segment is expected to dominate the market.

Psoriasis is a chronic autoimmune condition affecting the skin of a patient. The condition results from hyperactivity of immune cells, especially the interleukins, and is characterized by epidermal hyperplasia and infiltration of immune cells into the skin layers. The IL-23/IL-17 axis is the major driver for the disease whose activation results in a cascade of events such as the release of cytokines, inflammatory mediators, and then activation of keratinocytes. This activation may lead to excessive inflammation and ultimately the condition called psoriasis. There are different types of psoriasis, of which plaque psoriasis is the most common one characterized by red patchy skin and white scales. Moreover, psoriasis patients are at higher risk of developing other inflammatory conditions such as psoriatic arthritis, severe cardiovascular events, etc.

Although the currently approved interleukin inhibitors are indicated in various chronic inflammatory conditions, most of them were first approved for the treatment of one or the other kind of psoriasis and its related complications. However, the prevalence of psoriasis is also high, and as per the National Psoriasis Foundation, there were nearly 125 million affected with psoriasis worldwide.

Geographical Analysis

North America is expected to hold a significant share of the interleukin inhibitors market.

North America currently holds a significant market share in the interleukin inhibitors market due to various factors including, higher demand for novel therapies, major revenue generated by market players, and increasing prevalence of chronic inflammatory conditions. Any emerging drug is expected to first get launched in the U.S. market due to higher demand, and all the interleukin inhibitors in the current market were first launched in the U.S., providing first access to the patients in the country. Due to higher per-capita income and spending on healthcare, the interleukin inhibitors are sold at higher prices in the North America market as compared to other nations. Due to this, manufacturers generate a majority of their revenue from the region.

For instance, below are the top 10 selling interleukin inhibitors and their revenue share from the U.S. market.

Competitive Landscape

The major global players in the interleukin inhibitors market are Sanofi, Regeneron Pharmaceuticals, Inc., Novartis AG, Eli Lilly and Company, GSK plc., Johnson & Johnson Services, Inc., AstraZeneca., AbbVie., F. Hoffmann-La Roche Ltd, Sun Pharmaceutical Industries, Inc., Ortho Dermatologics' affiliated entities., Sobi, Inc., UCB, Inc., Teva Pharmaceutical Industries Ltd., LEO Pharma Inc., Kiniksa Pharmaceuticals., Boehringer Ingelheim International GmbH., and Galderma Laboratories, L.P. among others.

Emerging Players

The emerging players in the interleukin inhibitors market include AnaptysBio, Inc., Huabo Biopharm (Shanghai) Co., Ltd., CSL, and DICE Therapeutics among others.

Key Developments

  • In September 2024, the U.S. Food and Drug Administration (FDA) approved BIMZELX (bimekizumab-bkzx) for the treatment of adult patients with active psoriatic arthritis and active non-radiographic axial spondyloarthritis. Bimzelx developed by UCB, is an interleukin 17A & 17F inhibitor that is available in s.c. Injection is administered every four weeks.
  • In September 2024, the U.S. Food and Drug Administration (FDA) approved EBGLYSS (lebrikizumab-lbkz) for the treatment of adult and child patients above 12 years of age having moderate to severe atopic dermatitis. Ebglyss developed by Eli Lilly and Company is an IL-13 inhibitor available in i.v. formulation.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
  • Target Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Target delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global interleukin inhibitors market report would provide approximately 86 tables, 69 figures, and 265 pages.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Target
  • 3.2. Snippet by Indication
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Incidence of Chronic Inflammatory Conditions
      • 4.1.1.2. Rising Product Approvals and Market Access
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Interleukin Inhibitors
    • 4.1.3. Opportunities
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Epidemiology
  • 5.3. Pricing Analysis
  • 5.4. Pipeline Analysis
  • 5.5. Patent Analysis
  • 5.6. Regulatory Analysis

6. By Target

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target
    • 6.1.2. Market Attractiveness Index, By Target
  • 6.2. Interleukin-1*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Interleukin-2
  • 6.4. Interleukin-6
  • 6.5. Interleukin-12
  • 6.6. Interleukin-17
  • 6.7. Interleukin-23
  • 6.8. Others

7. By Indication

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 7.1.2. Market Attractiveness Index, By Indication
  • 7.2. Psoriasis*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Atopic Dermatitis
    • 7.2.4. Arthritis
    • 7.2.5. Asthma
    • 7.2.6. Inflammatory Bowel Disease (IBD)
    • 7.2.7. Others

8. By Distribution Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.1.2. Market Attractiveness Index, By Distribution Channel
  • 8.2. Hospital Pharmacies*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Retail Pharmacies
  • 8.4. Online Pharmacies

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Spain
      • 9.3.6.5. Italy
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

Key Market Players

  • 11.1. Sanofi*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio
      • 11.1.2.1. Product Description
      • 11.1.2.2. Product Key Performance Indicators (KPIs)
      • 11.1.2.3. Historic and Forecasted Product Sales
      • 11.1.2.4. Product Sales Volume
    • 11.1.3. Financial Overview
      • 11.1.3.1. Company Revenue's
      • 11.1.3.2. Geographical Revenue Shares
      • 11.1.3.3. Revenue Forecasts
    • 11.1.4. Key Developments
      • 11.1.4.1. Mergers & Acquisitions
      • 11.1.4.2. Key Product Development Activities
      • 11.1.4.3. Regulatory Approvals etc.
    • 11.1.5. SWOT Analysis
  • 11.2. Regeneron Pharmaceuticals, Inc.
  • 11.3. Novartis AG
  • 11.4. Eli Lilly and Company
  • 11.5. GSK plc.
  • 11.6. Johnson & Johnson Services, Inc.
  • 11.7. AstraZeneca.
  • 11.8. AbbVie.
  • 11.9. F. Hoffmann-La Roche Ltd
  • 11.10. Sun Pharmaceutical Industries, Inc.
  • 11.11. Ortho Dermatologics' affiliated entities.
  • 11.12. Sobi, Inc.
  • 11.13. UCB, Inc.
  • 11.14. Teva Pharmaceutical Industries Ltd.
  • 11.15. LEO Pharma Inc.
  • 11.16. Kiniksa Pharmaceuticals.
  • 11.17. Boehringer Ingelheim International GmbH.
  • 11.18. Galderma Laboratories, L.P.
  • Similar data will be provided for each market player.

Emerging Market Players

  • 11.19. AnaptysBio, Inc.
    • 11.19.1. Pipeline Products Description
    • 11.19.2. Product Key Performance Indicators (KPIs)
    • 11.19.3. Key Activities
    • 11.19.4. Market Entry Timelines
    • 11.19.5. Product Penetration Rate
    • 11.19.6. Sales Estimation and Projections
  • 11.20. Huabo Biopharm (Shanghai) Co., Ltd.
  • 11.21. CSL
  • 11.22. DICE Therapeutics
  • Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us